LENSAR Inc (LNSR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LENSAR Inc (LNSR) has a cash flow conversion efficiency ratio of 0.290x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.51 Million) by net assets ($-12.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of LENSAR Inc to measure how much of total assets are equity-financed.
LENSAR Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how LENSAR Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LENSAR Inc (LNSR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
LENSAR Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LENSAR Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thai Wacoal Public Company Limited
BK:WACOAL
|
-0.002x |
|
Largo Resources Ltd
TO:LGO
|
-0.092x |
|
TEAM INC. DL-30
F:T9CA
|
-0.685x |
|
Fy Grp Ltd
TW:6807
|
0.016x |
|
ALT Telecom Public Company Limited
BK:ALT
|
-0.053x |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
-0.033x |
|
LTR Pharma Ltd
AU:LTP
|
-0.089x |
|
OKYO Pharma Ltd ADR
NASDAQ:OKYO
|
0.448x |
Annual Cash Flow Conversion Efficiency for LENSAR Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of LENSAR Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see LENSAR Inc (LNSR) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $18.65 Million | $-2.27 Million | -0.122x | +40.41% |
| 2023-12-31 | $47.18 Million | $-9.66 Million | -0.205x | +42.14% |
| 2022-12-31 | $41.98 Million | $-14.86 Million | -0.354x | -116.51% |
| 2021-12-31 | $54.88 Million | $-8.97 Million | -0.163x | +20.35% |
| 2020-12-31 | $67.21 Million | $-13.79 Million | -0.205x | -149.80% |
| 2019-12-31 | $-30.55 Million | $-12.59 Million | 0.412x | +347.34% |
| 2018-12-31 | $-20.46 Million | $-1.89 Million | 0.092x | -- |
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcom… Read more